Skip to content

Therapeutic effect of Xialiqi Capsule on benign prostatic hyperplasia

Therapeutic effect of Xialiqi Capsule on benign prostatic hyperplasia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005234
Enrollment
Unknown
Registered
2021-08-27
Start date
2021-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

Sponsors

Second Hospital of Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with BPH who have symptoms of frequent urination and dysuria, diagnosed by digital rectal examination, B-ultrasound, and uroflowmetry. 2. IPSS>=13 and/or QOL>=3 points. 3. Prostate volume > 25ml. 4. The maximum urine flow rate is less than 15ml/s. 5. Residual urine volume 50 years. 7. The patients voluntarily participated and signed the informed consent. 8. PSA4ng/ml, but exclude patients with prostate cancer. 9. In line with the dialectical standard of TCM spleen-kidney qi deficiency and phlegm stasis syndrome.

Exclusion criteria

Exclusion criteria: 1. With other diseases that cause urination disorders, such as prostate cancer. 2. The patient or his authorizer is unwilling to comply with the study protocol. 3. Upper urinary tract hydrops, bladder stones, repeated hematuria, urinary tract infections caused by benign prostatic hyperplasia. 4. Patients with benign prostatic hyperplasia who have failed invasive treatment and who have a history of pelvic surgery or injury. 5. Patients with severe diabetes, hypertension, cardiovascular and cerebrovascular diseases. 6. Patients with major organ dysfunction, such as liver and kidney insufficiency. 7. Psychopaths. 8. Those with allergies.

Design outcomes

Primary

MeasureTime frame
Prostatic hyperplasia I-PSS score;Maximum urinary flow rate;QOL Quality of life score;Average urinary flow rate;Score of deficiency in spleen and kidney and phlegm stasis syndrome;

Secondary

MeasureTime frame
Prostate volume;Chronic prostatitis symptom score;Residual urine volume;

Countries

China

Contacts

Public ContactLiu Liwei

Second Hospital of Tianjin Medical University

lwluu@aliyun.com+86 13752253408

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026